People and Business News — 6/21
The latest industry news of the past month, all in one place.
People News
Sharp has appointed Robert O’Beirn as Senior Vice President and Managing Director of its global Clinical Services business.
CROMSOURCE announced the appointment of Kris O’Brien as Global Head of TalentSource Life Sciences.
The IMA Group brought on Mike Minor as Executive Vice President of Clinical Research, and Debra Nichols as Senior Vice President of Commercial Affairs.
Clinical Ink announced the hiring of Janette Morgan as Executive Vice President, General Manager, EMEA.
Worldwide Clinical Trials, Inc. announced the promotion of Dave Bowser to Chief Operating Officer, and Sara Davis to Chief Commercial Officer.
Cytel Inc. has appointed Dr. Kyle Wathen as Vice President of Scientific Strategy and Innovation.
Signant Health announced the appointments of Jason Martin as Chief Operating Officer and Jean-Jacques Charhon as Chief Financial Officer.
Javara announced that it has appointed Brenda Reese as its first Chief Commercial Officer.
hyperCORE International chooses Seneca Harrison as their Internal Chief Diversity Officer.
Syneos Health announced the appointment of David S. Wilkes, MD, to the Company’s Board of Directors.
Business News
WCG IRB announced the launch of its 2021 International Fellows Program.
Yourway announced an expansion underway at its headquarters in Allentown, Pennsylvania, making the campus to over 300,000 square feet.
Recognition
Castor announced continued rapid adoption of its decentralized clinical trial platform to power COVID-19 studies globally.
OCT Clinical is among the top 3 CROs by the number of clinical trials launched in 2020, according to the Russian Registry of Clinical Trials.
Calyx announced that Calyx RIM has supported over 100 COVID-19 vaccine authorizations.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
